Targeting α7-nAChRs in combination with other systems—either pharmacologically or through precision-medicine approaches—may enhance therapeutic efficacy, minimize side effects, and address both motor and non-motor symptoms of Parkinson’s disease. The gene discussed is CHRNA7; the disease is Parkinson disease.